Here's Why Allergan Stock Might Be an Incredible Bargain After Dropping 9.9% in August


The specialty drugmaker's shares were apparently brought down by its loose association with Teva Pharmaceutical Industries Ltd. via its 9.9% stake in the Israeli drugmaker, as well as its former ties to the struggling generic drug industry. As a reminder, Allergan sold its massive generic drug business to Teva last year in an equity and cash deal valued at $40.5 billion.



from Biotech News